Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bavarian Nordic A/S (OP: BVNKF )

28.13 UNCHANGED
Streaming Delayed Price Updated: 1:32 PM EST, Nov 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50
Open 28.13
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 28.13
Today's Range 28.13 - 28.13
52wk Range 18.72 - 46.05
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UK Secures Additional Doses Of Bavarian Nordic Mpox Vaccine To Combat New Variant Threat
The UK government has purchased 150,000 mpox vaccine doses from Bavarian Nordic, enhancing its response to clade I mpox, while partnering with WHO and UNICEF. 
Via Benzinga
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys. 
Via Benzinga

Performance

YTD
+13.71%
+13.71%
1 Month
-13.69%
-13.69%
3 Month
-31.34%
-31.34%
6 Month
N/A
N/A
1 Year
+19.70%
+19.70%

More News

Read More
Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic
Via Benzinga
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Via Benzinga
Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency
Via Benzinga
Bavarian Nordic Recruits US Firm For Packaging Services For Its Monkeypox Vaccine
Via Benzinga
Bavarian Nordic's Monkeypox Vaccine Gets Thumbs Up From EU Regulator
Via Benzinga
Monkeypox Vaccine Maker Bavarian Nordic Bets $380M On Emergent Bio's Travel Vaccines
Via Benzinga
West Africa-Based Studies Show JNJ, Merck's Ebola Vaccines Provide Lasting Antibodies
Via Benzinga
Threats For New Outbreak Looms, As Scientists Signal Deadly Monkeypox Variant Circulating In Central Africa
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed
Via Benzinga
SIGA Tech Made The Smallpox Treatment As Post-9/11 Bioterrorism Defense: Report
Via Benzinga
Bavarian Nordic Making All Efforts To Stretch Capacity To Boost Monkeypox Vaccine Supplies
Via Benzinga
Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch
Via Benzinga
Applied DNA Seeks Approval For PCR-Based Monkeypox Virus Test
Via Benzinga
Biden Officials Seek To Boost Supply For Monkeypox Vaccines, Treatment
Via Benzinga
WeTrade Shares Soar On Collaboration Over Exclusive COVID-19 Omicron Disinfectant
Via Benzinga
A Biopharma Working On Malaria, Norovirus Vaccines Threw It's Hat In The Monkeypox Ring
Via Benzinga
Benzinga Before The Bell: More Amazon Workers Join Union Over Pay and Work Conditions, UK Inflation Highest In 40 Years, Sole Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand And Other Top Financial Stories Wednesday, August 17
Via Benzinga
The Only Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand
Via Benzinga
Bavarian Nordic's Monkeypox Vaccine Scores EU Approval As WHO Declares Global Health Emergency
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Via Benzinga
Bavarian Nordic Inks Multiple Supply Pact For Its Monkey pox Vaccine, Updates FY22 Guidance
Via Benzinga
Bavarian Nordic Launches COVID-19 Booster Study To Compare Against Pfizer/BioNTech Shot
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.